Ambusol is developing a first-in-class therapy targeting post-surgical glioblastoma cells using a proprietary amino acid analogue. Our platform offers a novel mechanism of action, a strong safety profile, and scalable manufacturing – designed to fill a critical gap in the brain cancer treatment landscape.
Strategic Advantages:
- Novel Mechanism: Exploits tumor-specific nutrient uptake pathways via System A transporters.
- Strong Preclinical Data: Efficacy and safety validated in multiple in vitro and in vivo models.
- Platform Technology: Potential applications beyond glioblastoma.
- Scalable Manufacturing: Ambient storage and simplified logistics.
- Large Market Opportunity: GBM has a high unmet need with limited treatment options.
- Experienced Team: Leadership includes biotech veterans and academic experts in oncology and transport biology.